{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T04:05:16Z","timestamp":1792209916148,"version":"4.4.0"},"reference-count":20,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005565","name":"Johnson & Johnson Innovative Medicine","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005565","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009032","name":"Pfizer Ltd","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009032","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JACC: Advances"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1016\/j.jacadv.2022.100148","type":"journal-article","created":{"date-parts":[[2022,12,14]],"date-time":"2022-12-14T14:03:19Z","timestamp":1671026599000},"page":"100148","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Improvements in Efficacy Measures With\u00a0Tafamidis in the Tafamidis in Transthyretin Cardiomyopathy Clinical\u00a0Trial"],"prefix":"10.1016","volume":"1","author":[{"given":"Mazen","family":"Hanna","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nowell M.","family":"Fine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Balarama","family":"Gundapaneni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marla B.","family":"Sultan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald M.","family":"Witteles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacadv.2022.100148_bib1","doi-asserted-by":"crossref","first-page":"2872","DOI":"10.1016\/j.jacc.2019.04.003","article-title":"Transthyretin amyloid cardiomyopathy: JACC state-of-the-art review","volume":"73","author":"Ruberg","year":"2019","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacadv.2022.100148_bib2","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1161\/CIRCULATIONAHA.111.078915","article-title":"Transthyretin (TTR) cardiac amyloidosis","volume":"126","author":"Ruberg","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.jacadv.2022.100148_bib3","doi-asserted-by":"crossref","first-page":"3875","DOI":"10.1002\/ehf2.13541","article-title":"Natural history and progression of transthyretin amyloid cardiomyopathy: insights from ATTR-ACT","volume":"8","author":"Nativi-Nicolau","year":"2021","journal-title":"ESC Heart Fail"},{"key":"10.1016\/j.jacadv.2022.100148_bib4","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1161\/CIRCULATIONAHA.118.038169","article-title":"Natural history, quality of life, and outcome in cardiac transthyretin amyloidosis","volume":"140","author":"Lane","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.jacadv.2022.100148_bib5","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.2147\/DDDT.S289772","article-title":"Drug discovery and development in rare diseases: taking a closer look at the tafamidis story","volume":"15","author":"Burton","year":"2021","journal-title":"Drug Des Devel Ther"},{"key":"10.1016\/j.jacadv.2022.100148_bib6","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","article-title":"Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy","volume":"379","author":"Maurer","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacadv.2022.100148_bib7","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1002\/ejhf.2027","article-title":"Efficacy and safety of tafamidis doses in the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR-ACT) and long-term extension study","volume":"23","author":"Damy","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jacadv.2022.100148_bib8","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.amjcard.2020.10.066","article-title":"Impact of tafamidis on health-related quality of life in patients with transthyretin amyloid cardiomyopathy (from the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial)","volume":"141","author":"Hanna","year":"2021","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacadv.2022.100148_bib11","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.116.003815","article-title":"Design and rationale of the phase 3 ATTR-ACT clinical trial (Tafamidis in Transthyretin Cardiomyopathy Clinical Trial)","volume":"10","author":"Maurer","year":"2017","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.jacadv.2022.100148_bib12","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1016\/j.jacc.2020.09.542","article-title":"Interpreting the Kansas city cardiomyopathy questionnaire in clinical trials and clinical care: JACC state-of-the-art review","volume":"76","author":"Spertus","year":"2020","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacadv.2022.100148_bib13","series-title":"Nomenclature and Criteria for Diagnosis of Diseases of the Heart and Great Vessels","first-page":"253","year":"1994"},{"key":"10.1016\/j.jacadv.2022.100148_bib14","article-title":"Clinical implications of the New York Heart Association classification","volume":"8","author":"Caraballo","year":"2019","journal-title":"J\u00a0Am Heart Assoc"},{"key":"10.1016\/j.jacadv.2022.100148_bib15","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.jacc.2006.02.061","article-title":"Short-term change in distance walked in 6\u00a0min is an indicator of outcome in patients with chronic heart failure in clinical practice","volume":"48","author":"Passantino","year":"2006","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacadv.2022.100148_bib16","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1053\/euhj.2002.3282","article-title":"One-year mortality among unselected outpatients with heart failure","volume":"23","author":"Muntwyler","year":"2002","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacadv.2022.100148_bib17","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1001\/jamacardio.2021.0372","article-title":"Comparison of New York Heart Association class and patient-reported outcomes for heart failure with reduced ejection fraction","volume":"6","author":"Greene","year":"2021","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jacadv.2022.100148_bib18","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.1161\/01.CIR.0000143059.68996.A7","article-title":"Prognostic impact of plasma N-terminal pro\u2013brain natriuretic peptide in severe chronic congestive heart failure","volume":"110","author":"Hartmann","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.jacadv.2022.100148_bib19","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1136\/heartjnl-2018-314173","article-title":"Prognosis and NT-proBNP in heart failure patients with preserved versus reduced ejection fraction","volume":"105","author":"Salah","year":"2019","journal-title":"Heart"},{"key":"10.1016\/j.jacadv.2022.100148_bib20","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1080\/02813432.2019.1684029","article-title":"Limited value of NT-proBNP as a prognostic marker of all-cause mortality in patients with heart failure with preserved and mid-range ejection fraction in primary care: a report from the Swedish Heart\u00a0Failure Register","volume":"37","author":"Eriksson","year":"2019","journal-title":"Scand J Prim Health Care"},{"key":"10.1016\/j.jacadv.2022.100148_bib21","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1016\/j.cardfail.2007.07.001","article-title":"Quality of life and prognosis in heart failure: results of the Beta-Blocker Evaluation of Survival Trial (BEST)","volume":"13","author":"Tate","year":"2007","journal-title":"J\u00a0Card Fail"},{"key":"10.1016\/j.jacadv.2022.100148_bib22","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1093\/eurheartj\/ehi162","article-title":"Six minute corridor walk test as an outcome measure for the assessment of treatment in randomized, blinded intervention trials of chronic heart failure: a systematic review","volume":"26","author":"Olsson","year":"2005","journal-title":"Eur Heart J"}],"container-title":["JACC: Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772963X22002253?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772963X22002253?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,9]],"date-time":"2025-11-09T00:37:27Z","timestamp":1762648647000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2772963X22002253"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":20,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["S2772963X22002253"],"URL":"https:\/\/doi.org\/10.1016\/j.jacadv.2022.100148","relation":{},"ISSN":["2772-963X"],"issn-type":[{"value":"2772-963X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Improvements in Efficacy Measures With\u00a0Tafamidis in the Tafamidis in Transthyretin Cardiomyopathy Clinical\u00a0Trial","name":"articletitle","label":"Article Title"},{"value":"JACC: Advances","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacadv.2022.100148","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation.","name":"copyright","label":"Copyright"}],"article-number":"100148"}}